Activation of peripheral cannabinoid CB1and CB2receptors suppresses the maintenance of inflammatory nociception: a comparative analysis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Effects of locally administered agonists and antagonists for cannabinoid CB 1 and CB 2 receptors on mechanical and thermal hypersensitivity were compared after the establishment of chronic inflammation. Experimental approach: Carrageenan was administered unilaterally to the rat hindpaw on day 1. Prophylactic efficacy of locally administered CB 1‐ and CB 2‐selective agonists −arachidonyl‐2‐chloroethylamide (ACEA) and (R,S)‐(2‐iodo‐5‐nitro‐phenyl)‐[l‐(l‐methyl‐piperidin‐2‐ylmethyl)‐l H‐ubdik‐3‐yl]‐methanone ((R,S)‐AM1241), respectively− on mechanical and thermal hypersensitivity were compared on day 2. Pharmacological specificity was evaluated using locally administered CB 1 and CB 2‐selective antagonists −N‐(piperidin‐1‐yl)‐5‐(4‐chlorophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methyl‐1 H‐pyrazole‐3‐carboxamidehydrochloride (SR141716A) and N‐[(1S)‐endo‐1,3,3‐trimethyl bicycle [2.2.1] heptan‐2‐yl]‐5‐(4‐chloro‐3‐methylphenyl)‐1‐(4‐methylbenzyl)‐pyrazole‐3‐carboxamide (SR144528), respectively. Key Results: Administration of either ACEA or AM1241 to the inflamed but not noninflamed paw suppressed the maintenance of carrageenan‐evoked mechanical hyperalgesia and tactile allodynia and attenuated thermal hyperalgesia. The ACEA‐induced suppression of mechanical and thermal hypersensitivity was blocked by local injection of SR141716A but not SR144528. AM1241 suppressed mechanical hypersensitivity with the reverse pharmacological specificity. The AM1241‐induced suppression of thermal hyperalgesia was blocked by SR144528 and to a lesser extent by SR14176A. Co‐administration of ACEA with AM1241 in the inflamed paw increased the magnitude but not the duration of thermal antihyperalgesia compared to intraplantar administration of either agonist alone. Conclusions and Implications: Cannabinoids act locally through distinct CB 1 and CB 2 mechanisms to suppress mechanical hypersensitivity after the establishment of chronic inflammation, at doses that produced modest changes in thermal hyperalgesia. Additive antihyperalgesic effects were observed following prophylactic co‐administration of the CB 1‐ and CB 2‐selective agonists. Our results suggest that peripheral cannabinoid antihyperalgesic actions may be exploited for treatment of inflammatory pain states. British Journal of Pharmacology(2007)150, 153–163. doi:10.1038/sj.bjp.0706984
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ethical guidelines for investigations of experimental pain in conscious animals.
Zimmermann, M. (1983) · Pain · doi:10.1016/0304-3959(83)90201-4 · Cited by 7,762 · cited 1×
“All procedures were approved by the University of Georgia Animal Care and Use Committee and followed the guidelines for the treatment of animals of the International Association for the Study of Pain (Zimmermann, 1983).”
MethodMolecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 6×
“Whereas CB1 is expressed primarily in the central nervous system (CNS) (Matsuda et al., 1990; Munro et al., 1993; Zimmer et al., 1999), CB2 is expressed predominantly, but not exclusively (Van Sickle et al., 2005; Beltramo et al., 2006), outside the CNS (Munro et al., 1993; Zimmer et al., 1999; Buckley et al., 2000) a…”
BackgroundInfluentialStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 5×
“Whereas CB1 is expressed primarily in the central nervous system (CNS) (Matsuda et al., 1990; Munro et al., 1993; Zimmer et al., 1999), CB2 is expressed predominantly, but not exclusively (Van Sickle et al., 2005; Beltramo et al., 2006), outside the CNS (Munro et al., 1993; Zimmer et al., 1999; Buckley et al., 2000) a…”
BackgroundInfluentialIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Self-citationZhang, J., Hoffert, C., Vu, H. K., Groblewski, T., Ahmad, S., & O'Donnell, D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02704.x · Cited by 419
Hohmann, A. G., & Herkenham, M. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00524-7 · Cited by 301
Self-citationCB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms
Beltramo, M., Bernardini, N., Bertorelli, R., Campanella, M., Nicolussi, E., Fredduzzi, S., & Reggiani, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04684.x · Cited by 290
Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons
Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S., & Winter, J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.06.009 · Cited by 251 · cited 1×
“Finally, expression of CB2 is markedly upregulated in the dorsal root ganglia and spinal cord following sciatic nerve injury (Zhang et al., 2003; Wotherspoon et al., 2005; Beltramo et al., 2006), whereas expression levels remain near the threshold for detection in naive animals.”
BackgroundInfluentialCB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
Clayton, N., Marshall, F. H., Bountra, C., & O'Shaughnessy, C. T. (2002) · Pain · doi:10.1016/s0304-3959(01)00454-7 · Cited by 247
Elmes, S. J. R., Jhaveri, M. D., Smart, D., Kendall, D. A., & Chapman, V. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03690.x · Cited by 160
Cited by
Guindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423
Self-citationDonvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Hsieh, G. C., Pai, M., Chandran, P., Hooker, B. A., Zhu, C. Z., Salyers, A. K., Wensink, E. J., Zhan, C., Carroll, W. A., Dart, M. J., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01046.x · Cited by 139
Galdino, G., Romero, T., Pinho da Silva, J. F., Aguiar, D., de Paula, A. M., Cruz, J., Parrella, C., Piscitelli, F., Duarte, I., Di Marzo, V., et al. (2014) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000000340 · Cited by 72
Desroches, J., Guindon, J., Lambert, C., & Beaulieu, P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.322 · Cited by 63
“Moreover, it has been suggested that cannabinoids can exert their anti-nociceptive action through peripheral mechanisms involving CB1 and CB2 receptors (Sokal et al., 2003; Elmes et al., 2004; Jhaveri et al., 2006; Gutierrez et al., 2007).”
BackgroundNegrete, R., Hervera, A., Leánez, S., Martín-Campos, J. M., & Pol, O. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026688 · Cited by 33
“Several works demonstrated that the local administration of CB2R selective agonists attenuates the thermal and mechanical hypersensitivity induced by carrageenan or CFA in different models of acute (hours to two days) inflammatory pain [2,8,20].”
McGaraughty, S., Chu, K. L., Dart, M. J., Yao, B. B., & Meyer, M. D. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.015 · Cited by 31
Metadata
- Authors
- Gutierrez, T., Farthing, J. N., Zvonok, A. M., Makriyannis, A., & Hohmann, A. G.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 150
- Issue
- 2
- Pages
- 153-163
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2064907044
- Cited by
- 105
- References
- 11
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.